ALTS

Company Overview — What Does ALT5 Sigma Corp Do?

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through three segments: Biotechnology, Recycling, and Technology. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs; and designs, develops, and sells cellular transceiver modules and associated wireless services. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada. ALT5 Sigma Corp (ALTS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Antonios Isaac and employs approximately 170 people, headquartered in LAS VEGAS, Nevada. With a market capitalization of $139M, ALTS is one of the notable companies in the Healthcare sector.

ALT5 Sigma Corp (ALTS) Stock Rating — Avoid (April 2026)

As of April 2026, ALT5 Sigma Corp receives a Avoid rating with a composite score of 22.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ALTS ranks #4,219 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ALT5 Sigma Corp ranks #753 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ALTS Stock Price and 52-Week Range

ALT5 Sigma Corp (ALTS) currently trades at $0.94. The stock lost $0.14 (13.1%) in the most recent trading session. The 52-week high for ALTS is $10.95, which means the stock is currently trading -91.4% from its annual peak. The 52-week low is $1.07, putting the stock -12.7% above its annual trough. Recent trading volume was 8.4M shares, reflecting moderate market activity.

Is ALTS Overvalued or Undervalued? — Valuation Analysis

ALT5 Sigma Corp (ALTS) carries a value factor score of 34/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 3.92x, compared to the Healthcare sector average of 23.63x — a discount of 83%. The price-to-book ratio stands at 0.09x, versus the sector average of 2.75x. The price-to-sales ratio is 5.69x, compared to 1.66x for the average Healthcare stock.

At current multiples, ALT5 Sigma Corp trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ALT5 Sigma Corp Profitability — ROE, Margins, and Quality Score

ALT5 Sigma Corp (ALTS) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 2.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at 2.2% versus the sector average of -33.1%.

On a margin basis, ALT5 Sigma Corp reports gross margins of 43.2%, compared to 71.5% for the sector. The operating margin is -78.8% (sector: -66.1%). Net profit margin stands at 105.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -37.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ALTS Debt, Balance Sheet, and Financial Health

ALT5 Sigma Corp has a debt-to-equity ratio of 5.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.79x, which may signal near-term liquidity tightness.

ALTS has a beta of 1.36, meaning it is more volatile than the broader market — a $10,000 investment in ALTS would be expected to move 36.1% more than the S&P 500 on any given day. The stability factor score for ALT5 Sigma Corp is 20/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ALT5 Sigma Corp Revenue and Earnings History — Quarterly Trend

In TTM 2026, ALT5 Sigma Corp reported revenue of $24M and earnings per share (EPS) of $0.67. Net income for the quarter was $35M. Gross margin was 43.2%. Operating income came in at $-22M.

In Q3 2025, ALT5 Sigma Corp reported revenue of $8M and earnings per share (EPS) of $0.67. Net income for the quarter was $49M. Gross margin was 34.6%. Revenue grew 53.3% year-over-year compared to Q3 2024. Operating income came in at $-17M.

In Q2 2025, ALT5 Sigma Corp reported revenue of $6M and earnings per share (EPS) of $-0.49. Net income for the quarter was $-9M. Gross margin was 43.5%. Operating income came in at $-2M.

In Q1 2025, ALT5 Sigma Corp reported revenue of $6M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-3M. Gross margin was 47.0%. Operating income came in at $-2M.

Over the past 8 quarters, ALT5 Sigma Corp has demonstrated a growth trajectory, with revenue expanding from $12M to $24M. Investors analyzing ALTS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ALTS Dividend Yield and Income Analysis

ALT5 Sigma Corp (ALTS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ALTS Momentum and Technical Analysis Profile

ALT5 Sigma Corp (ALTS) has a momentum factor score of 13/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 39/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

ALTS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ALT5 Sigma Corp (ALTS) ranks #753 out of 838 stocks based on the Blank Capital composite score. This places ALTS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ALTS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ALTS vs S&P 500 (SPY) comparison to assess how ALT5 Sigma Corp stacks up against the broader market across all factor dimensions.

ALTS Next Earnings Date

No upcoming earnings date has been announced for ALT5 Sigma Corp (ALTS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ALTS? — Investment Thesis Summary

The quantitative profile for ALT5 Sigma Corp suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 34/100 indicates premium valuation. Momentum is weak at 13/100, a headwind for near-term performance. High volatility (stability score 20/100) increases portfolio risk.

In summary, ALT5 Sigma Corp (ALTS) earns a Avoid rating with a composite score of 22.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ALTS stock.

Related Resources for ALTS Investors

Explore more research and tools: ALTS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ALTS head-to-head with peers: ALTS vs AZN, ALTS vs SLGL, ALTS vs VMD.